How profitable is Mettler-Toledo International Inc. (MTD)?

In FY 2025 (10-K), MTD converted $4.0B of revenue into a 59.4% gross margin, 25.5% operating margin, and $848.6M in free cash flow (21.1% FCF margin).

Stock Ratings / Health Care / MTD / financials

WAT (72) A (72) RVTY (65) AVTR (56) ⌘ Pro Terminal →

Mettler-Toledo International Inc. (MTD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1,674.81 -2.55% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1,671.14

Mettler-Toledo International Inc. (MTD) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (59.4% gross margin, 30% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $33.56B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MTD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MTD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Mettler-Toledo International Inc. (NYSE: MTD) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $1,674.81 (-2.55% 1D, market cap $33.56B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, MTD ranks #20 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MTD compare to WAT and A in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), MTD carries a Roarable B+ (78/100 RQD), trailing P/E of 39.6x, gross margin of 59.4%, and ROIC of 30.4%. By comparison, WAT (Waters Corporation) holds a B grade (72/100 RQD, P/E 73.4x, ROIC 16.8%, cap $45.46B) and A (Agilent Technologies Inc.) posts a B grade (72/100 RQD, P/E 39.2x, ROIC 15.3%, cap $49.30B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MTD?

▼

Per MTD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001037646), Mettler-Toledo International Inc. generated $4.03B in revenue (+4.0% YoY), $869.2M in net income, and $848.6M in free cash flow against $3.71B in total assets and $2.09B in total debt. Key quantitative strengths: Strong cash generator (59.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 40x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1,671.13 (-0.22%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 21.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 78/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.9% avg 90D alpha vs SPY • 70.6% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MTD)Realized 20D OHLCV Swing Band: ±4.9%

Deterministic 5-Pillar Attribution (78/100 Composite)

🔍 WHY MTD SCORES 78/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (24% of score)

20D Institutional Volume Accumulation (±4.9% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+18/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 21.1% FCF Margin ($848.6M FCF) & 59.4% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$1,609.27+4.3% Next Q

Q2 (-2Q)

Grade B$1,677.94+1.2% Next Q

Q3 (-1Q)

Grade B+$1,698.47-1.4% Next Q

Current

Grade B+$1,674.81+7.9% Hist 90D α

Trajectory: B (70) → B+ (78)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MTD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 78/100 (B+) score, MTD faces multiple-compression risk if 39.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 40x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 56.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1,512.37) or 200D SMA ($1,341.24) invalidates the momentum regime and cuts Target Base ($1,825.54) toward Bear Floor ($1,373.34).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MTD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MTD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 78%NO 22%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How MTD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$848.6M (21.1% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $3.79B

FY24

Rev $3.87B

FY25

Rev $4.03B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.03B	59.4%	25.5%	$869.2M	$848.6M	40.6%
FY 2024	$3.87B	60.1%	26.3%	$863.1M	$864.4M	48.9%
FY 2023	$3.79B	59.4%	24.6%	$788.8M	$795.4M	6.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MTD)

✓Walkthrough of MTD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MTD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.86%▲ ASCENDING CHANNEL

2026-11-03O $1,718.6H $1,718.6L $1,674.8C $1,674.8VOL 189.7K

RES: $1,745.6SUP: $1,362.6SMA50: $1,512.4SMA200: $1,341.2

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MTD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MTD Butterfly Map → + Track MTD →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

30.2%/yr Implied 5Y Growth

vs. +4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MTD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MTD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MTD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MTD)

Health Care Rank #20 of 1015 ⚔️ WAT vs MTD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MTD vs. WAT, A, RVTY, AVTR)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Mettler-Toledo International Inc. (MTD) ranks #20 by composite RQD confidence (78/100, grade B+) and #53 by equity capitalization ($33.56B). Within this direct 5-issuer industry benchmark cohort, A leads on earnings valuation at 39.2x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MTD ACTIVE Mettler-Toledo International Inc.	B+	78/100	39.6x	59.4%	30.4%	-2.55%	$33.56B	Benchmark Subject
WAT Waters Corporation	B	72/100	73.4x	59.3%	16.8%	-3.61%	$45.46B	/wat-vs-mtd →
A Agilent Technologies Inc.	B	72/100	39.2x	52.4%	15.3%	-3.47%	$49.30B	/a-vs-mtd →
RVTY Revvity Inc.	C	65/100	76.7x	—	3.1%	-5.30%	$17.52B	/rvty-vs-mtd →
AVTR Avantor Inc.	D+	56/100	—	32.7%	-2.1%	-3.78%	$10.88B	/avtr-vs-mtd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001037646 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mettler-Toledo International Inc. (MTD) reported GAAP revenue of $4.03B (+4.0% vs. FY2024 revenue of $3.87B , and +6.3% cumulative change since FY2023) , GAAP net income of $869.2M, operating cash flow of $955.8M, and free cash flow of $848.6M (-1.8% YoY). On the balance sheet, MTD closed FY2025 with $3.71B in total assets against $2.09B in total debt (Altman Z-Score: 11.09, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.03B	$869.2M	$955.8M	$848.6M	$3.71B	$2.09B
FY2024 (FY)	2024-12-31	$3.87B	$863.1M	$968.3M	$864.4M	$3.24B	$1.83B
FY2023 (FY)	2023-12-31	$3.79B	$788.8M	$965.9M	$795.4M	$18.94B	$4.43B

3. MTD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MTD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MTD compare to WAT and A in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MTD?

Where is MTD trading relative to its 50-day, 200-day, and 52-week technical levels?

MTD last traded at $1,674.81 (-2.55% on volume of 189,705 shares), positioning the stock +10.74% above its 50-day simple moving average ($1,512.37) and +24.87% above its 200-day simple moving average ($1,341.24). Across its 52-week range of $1,023.05 to $1,728.66, MTD sits at the 92.4% percentile with a 14-day RSI of 60.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.9% ($1,592.74 to $1,756.88).

Direct Sub-Reports: MTD RQD Cockpit MTD 12M Forecast MTD Earnings & Move MTD Dividends & DRIP MTD Insiders & 13F MTD Whale Options MTD Profit Sankey MTD News & Why

ROARABLE RATING BRIEF • RQD 78/100 (B+) ✓ SEC XBRL & RQD VERIFIED

MTD — Mettler-Toledo International Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Mettler-Toledo International Inc. (MTD) earns a live Roarable RQD composite score of 78/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $1,674.81 (-2.55% 1D, market capitalization $33.56B).

Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 30.4%, gross margin of 59.4%, operating margin of 26.3%, and free cash flow yield of 2.46%.
Whale 13F & Options Flow (19/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (13/20) + Forensic Balance Sheet (16/20): Incorporates a 0.87x equity beta, Altman Z-Score of 11.09, Piotroski F-Score of 8/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Mettler-Toledo International Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry,. The company generated revenue of $4.03B in FY 2025, indicating a sizable operating business.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Mettler-Toledo International Inc. (MTD) reported $4.03B in annual revenue (up from $3.87B in FY2024, +4.0% YoY) and $869.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.79B revenue, $788.8M net income) through FY2025, MTD scaled operating cash flow to $955.8M and free cash flow to $848.6M, backed by $3.71B in total assets against $2.09B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B+ • RQD 78/100): Strong cash generator (59.4% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $1,023.05 – $1,728.66 52-week range.
🐻 Primary Bear Case & Valuation Risk: Priced at 40x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 39.6x trailing P/E and 31.7x EV/EBITDA against 26.3% operating margins and a 0.87x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Laboratory Analytical Instruments (Health Care), MTD carries a macro regime beta of 0.87 and gross margin of 59.4%.

Key Question #1: Can MTD sustain or expand its 26.3% operating margin and 30.4% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $4.03B and free cash flow of $848.6M, how will capital allocation balance growth reinvestment against $2.09B in total debt?
Key Question #3: How sensitive is MTD's 36.8x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.87x)?

MTD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Mettler-Toledo International Inc. (MTD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MTD Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 22h ago

Shares Of Mettler-Toledo International Are Still Too Pricey For My Liking (NYSE:MTD)

Seeking Alpha report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Mettler-Toledo International Inc. to Host Investor Meeting

Yahoo Finance report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Mettler-Toledo International, Inc. Stock 12‑Month Price Target Raised to $1544.42

TradingView report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

JPMorgan Adjusts Price Target on Mettler-Toledo International to $1,550 From $1,400

Yahoo Finance report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Mettler-Toledo International, Inc. $MTD Stock Position Lessened by Robeco Schweiz AG

MarketBeat report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Mettler Toledo International (MTD) Could Be 9% Above Fair Value As Momentum Builds

Simply Wall St report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Mettler-Toledo (MTD): AI-Driven Pharma R&D Productivity Catalyzes Growth

Yahoo Finance report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Barclays Forecasts Strong Price Appreciation for Mettler-Toledo International (NYSE:MTD) Stock

MarketBeat report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MTD Bull vs. Bear Conversation Board — What's Your Call at $1,674.81?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MTD 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $2,160.50 (+29.0%)

📌 Pinned Debate

Returns on capital are exceptional, with ROIC of 30.4% and an Altman Z-Score of 11.09 signaling strong quality and financial health.

The street is overcomplicating Mettler-Toledo International Inc. (MTD). Returns on capital are exceptional, with ROIC of 30.4% and an Altman Z-Score of 11.09 signaling strong quality and financial health.. With an RQD score of 78/100 (B+) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1808.79.

SectorRotator 🐂 BULL

@MacroHawk_NYC Agree on the RQD 78/100 quality, though with 0.87 beta I'm scaling in with half-size at $1674.81 and keeping dry powder in case we test $1557.57.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1,323.10 (-21.0%)

Spot @ $1,674.81

The stock trades at a P/E (TTM) of 39.6 and an FCF yield of only 2.46%, leaving limited room for error if growth slows.

The stock trades at a P/E (TTM) of 39.6 and an FCF yield of only 2.46%, leaving limited room for error if growth slows.. Look at the math on MTD: paying 39.6x trailing P/E for 30.4% ROIC and 26.3% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $1473.83 before getting long.